search
Back to results

Extracorporeal Shockwave Therapy in Insertional Achilles Tendinopathy

Primary Purpose

Insertional Achilles Tendinopathy

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Extracorporeal Shock Wave Therapy
Sham Control group
Sponsored by
Mahidol University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Insertional Achilles Tendinopathy focused on measuring Insertional Achilles Tendinopathy, Extracorporeal Shock Wave Therapy, Double-blind Randomized Controlled Trial

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Diagnosed as insertional Achilles tendinopathy
  • Have symptom at least 6 months
  • Willing to participate

Exclusion Criteria:

  • History of peritendinous steroid injections within 4 weeks
  • Neurological conditions
  • Local skin infection
  • Ankle arthritis, traumatic, inflammation or deformity of ankle
  • History of ankle surgery
  • Contraindication for ESWT : Hemophilia, Coagulopathy

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Sham Comparator

    Arm Label

    Shock Wave group

    Sham Control group

    Arm Description

    Applying shock wave to patient's Achilles tendon insertion

    Applying sham shock wave to patient's Achilles tendon insertion

    Outcomes

    Primary Outcome Measures

    Visual Analog Scale
    Visual Analog Scale of Pain on Achilles tendon, range 0-10, 0 means no pain and 10 is the most severe pain

    Secondary Outcome Measures

    Visual Analog Scale - Foot and Ankle Thai version
    Range 0-100, 0 is worse, 100 is the best. Having 20 questions. Categorized into Pain, Function and other complaints
    The amount of rescue drug use
    Tablet/day,if amount of drug use is higher mean it is worse
    Complications
    Investigator collected complication such as pain during procedure, tendon rupture, or surgical rate and calculated the NNH

    Full Information

    First Posted
    September 4, 2018
    Last Updated
    September 22, 2018
    Sponsor
    Mahidol University
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03683641
    Brief Title
    Extracorporeal Shockwave Therapy in Insertional Achilles Tendinopathy
    Official Title
    Extracorporeal Shockwave Therapy in Insertional Achilles Tendinopathy
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    September 2018
    Overall Recruitment Status
    Completed
    Study Start Date
    July 4, 2016 (Actual)
    Primary Completion Date
    June 28, 2018 (Actual)
    Study Completion Date
    July 31, 2018 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Mahidol University

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    There is still limited number of studies in the literature provides insufficient evidence to support the use of ESWT in the treatment of insertional Achilles tendinopathy and the contribution of a placebo effect to the shock waves was not assessed by previous study. So the investigators conducted a double-blinded randomized-controlled trial at the orthopedic out-patient clinic, Department of Orthopedics, Faculty of Medicine Ramathibodi Hospital between December 2016 and June 2018. Hypothesized that ESWT might be effective on insertional Achilles tendinopathy
    Detailed Description
    Participants aged 18-70 years old who were diagnosed as insertional Achilles tendinopathy by foot and ankle specialists: had symptoms of pain and swelling at Achilles insertion more than 6 months; failed other standard conservative treatments for 3 months, i.e., rest, medication, activity modification, stretching exercise, and heel lift orthosis; be able to complete questionnaires; and willing to participate were enrolled. A computerized block-of-four random numbers were generated into 2 groups; ESWT and placebo (sham) group. Investigators concealed the treatment allocation by sequential sealed opaque envelops. The sealed opaque envelops were opened just before the assigned treatment began. The outcome assessment in this study was seven times at pre-intervention, 2nd, 3rd, 4th, 6th, 12th and 24th weeks. The participants had to complete questionnaire of VAS and VAS-FA Thai version. The investigators used mean and standard deviation for continuous variables, and frequency (%) for categorical data. For non-normally distributed variables, median and range was presented. Continuous data of both interventions was compared using either unpaired t-test or Mann-Whitney U test based on normal distribution. While categorical data was compared using Fisher's exact test. Repeated measures with Bonferroni post hoc analysis was applied for each intervention according to times of follow-up, and between groups. Bartlett's test for equal variances was checked the assumption before using analysis of variance. If the data did not meet the assumption, non-parametric Kruskal-Wallis was performed. The investigators used STATA 15.0 Program, College Station, Texas, USA for all statistical analysis. P-value < 0.05 defined as a significant level. Sample size was estimated using STATA 15.0 Program based on alpha error 0.05, beta error 0.2, mean VAS in controls 5.0, mean VAS in intervention group 3.5, standard deviation (SD) of both group 2.3,(13) pre-intervention assessment for 1 time, post-intervention assessment for 6 times, correlation between the first and the last VAS assessment 0.8. The calculated sample size was 12 per group. With 20% increment for loss of follow-up, the final sample size was 15 per group. All of them remained in the randomized groups and analyzed as intention-to-treat basis.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Insertional Achilles Tendinopathy
    Keywords
    Insertional Achilles Tendinopathy, Extracorporeal Shock Wave Therapy, Double-blind Randomized Controlled Trial

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    30 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Shock Wave group
    Arm Type
    Active Comparator
    Arm Description
    Applying shock wave to patient's Achilles tendon insertion
    Arm Title
    Sham Control group
    Arm Type
    Sham Comparator
    Arm Description
    Applying sham shock wave to patient's Achilles tendon insertion
    Intervention Type
    Device
    Intervention Name(s)
    Extracorporeal Shock Wave Therapy
    Intervention Description
    Use ESWT on chronic insertional Achilles tendinopathy
    Intervention Type
    Device
    Intervention Name(s)
    Sham Control group
    Intervention Description
    Use sham ESWT on chronic insertional Achilles tendinopathy
    Primary Outcome Measure Information:
    Title
    Visual Analog Scale
    Description
    Visual Analog Scale of Pain on Achilles tendon, range 0-10, 0 means no pain and 10 is the most severe pain
    Time Frame
    Up to 24 weeks
    Secondary Outcome Measure Information:
    Title
    Visual Analog Scale - Foot and Ankle Thai version
    Description
    Range 0-100, 0 is worse, 100 is the best. Having 20 questions. Categorized into Pain, Function and other complaints
    Time Frame
    Up to 24 weeks
    Title
    The amount of rescue drug use
    Description
    Tablet/day,if amount of drug use is higher mean it is worse
    Time Frame
    Up to 24 weeks
    Title
    Complications
    Description
    Investigator collected complication such as pain during procedure, tendon rupture, or surgical rate and calculated the NNH
    Time Frame
    Up to 52 weeks

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    70 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Diagnosed as insertional Achilles tendinopathy Have symptom at least 6 months Willing to participate Exclusion Criteria: History of peritendinous steroid injections within 4 weeks Neurological conditions Local skin infection Ankle arthritis, traumatic, inflammation or deformity of ankle History of ankle surgery Contraindication for ESWT : Hemophilia, Coagulopathy

    12. IPD Sharing Statement

    Learn more about this trial

    Extracorporeal Shockwave Therapy in Insertional Achilles Tendinopathy

    We'll reach out to this number within 24 hrs